Pre-Approval Information Exchange Act of 2022
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Nov 15, 2022)
Pre-Approval Information Exchange Act of 2022
This bill specifies that product information that is exchanged between drug manufacturers and certain health care entities (e.g., formulary committees) about drug products before regulatory approval is not considered to be misbranding if it relates to the product's investigational use and meets other specified criteria. The Government Accountability Office must study the use and effects of such information.
What just happenedNov 16, 2022
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseNov 15, 2022
- Nov 16, 2022Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Nov 15, 2022IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Nov 15, 2022IntroReferralIntro-H
Introduced in House
- Nov 15, 2022IntroReferral1000
Introduced in House